Scholars Academic Journal of Biosciences
Abbreviated Key Title: Sch Acad J Biosci
ISSN 2347-9515 (Print) | ISSN 2321-6883 (Online)
Journal homepage: https://saspublishers.com
NIH National Library of Medicine National Center for Biotechnology Information
NLM ID:101629416
OPEN ACCESS
Agriculture

Dietary Strategies for Diabetes Management: Chemical Profiling and Antidiabetic Potential of Food-Derived Bioactives in Functional Foods for Metabolic Health

Maria safdar[1*], Munnaza Saeed[2], Hudda Ayub[3]

[1]Department of Chemistry, University of Agriculture Faisalabad 38000, Pakistan
[2,3]National institute of Food science and technology, Faculty of Food, Nutrition and Home Science, University of Agriculture Faisalabad 38000, Pakistan

DOI: https://doi.org/10.36347/sajb.2025.v13i09.002 | **Received:** 04.06.2025 | **Accepted:** 07.08.2025 | **Published:** 04.09.2025

***Corresponding author:** Maria safdar
Department of Chemistry, University of Agriculture Faisalabad 38000, Pakistan

Abstract **Original Research Article**

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia resulting from impaired insulin secretion, insulin resistance, or both. With the global burden of diabetes increasing at an alarming rate, dietary intervention has emerged as a crucial strategy for prevention and management. In recent years, functional foods and nutraceuticals have gained substantial attention for their potential to regulate glycemic control, enhance insulin sensitivity, and mitigate complications associated with diabetes. These bioactive compounds, derived from natural sources such as plants, herbs, fruits, and whole grains, exert antidiabetic effects through multiple mechanisms including antioxidant activity, anti-inflammatory responses, modulation of gut microbiota, and improvement of β-cell function. This review provides a comprehensive overview of the pathophysiology of diabetes, the role of oxidative stress and inflammation, and the therapeutic potential of key functional foods such as cinnamon, fenugreek, bitter melon, garlic, and ginger. Furthermore, the article discusses novel extraction technologies, analytical approaches for compound characterization, and regulatory perspectives.

Keywords: Functional foods, Nutraceuticals, Diabetes mellitus, Bioactive compounds, Antidiabetic potential.

INTRODUCTION

Global Burden of Diabetes

Diabetes mellitus, particularly Type 2 diabetes mellitus (T2DM), is a rapidly escalating global health challenge. According to the International Diabetes Federation (IDF), approximately 537 million adults (aged 20–79 years) were living with diabetes in 2021, and this number is projected to rise to 783 million by 2045 [1]. The majority of cases—more than 90%—are T2DM, a condition primarily associated with insulin resistance, poor dietary habits, sedentary lifestyles, and obesity. This global epidemic not only places a significant financial burden on healthcare systems but also contributes substantially to morbidity and mortality through complications such as cardiovascular disease, neuropathy, nephropathy, and retinopathy [2].

ROLE OF DIET IN DIABETES MANAGEMENT

Dietary habits are among the most crucial modifiable risk factors for the development and progression of T2DM. A well-structured dietary plan can help maintain glycemic control, improve insulin sensitivity, reduce weight, and delay or prevent complications [3]. Diets rich in whole grains, fiber, lean proteins, unsaturated fats, and low glycemic index (GI) carbohydrates have shown to be effective in controlling postprandial glucose levels and improving metabolic parameters [4]. Moreover, nutrition therapy is now recognized as a core component in both the prevention and treatment of diabetes, often showing results comparable to or synergistic with pharmacological interventions [5].

EMERGENCE OF FUNCTIONAL FOODS AND NUTRACEUTICALS

In recent years, the concept of functional foods—foods that provide health benefits beyond basic nutrition—has gained significant momentum. These foods are enriched with bioactive compounds such as polyphenols, flavonoids, alkaloids, peptides, and omega-3 fatty acids that have been scientifically demonstrated to exert antidiabetic, anti-inflammatory, and antioxidant effects [6]. The increasing prevalence of lifestyle-related diseases has fueled consumer interest in these health-promoting dietary options. Additionally, nutraceuticals, which are concentrated forms of food-derived compounds available as supplements, have been widely investigated for their role in glycemic control [7].

Together, functional foods and nutraceuticals are forming the basis for dietary-based interventions in metabolic health, with particular emphasis on diabetes management. Their inclusion in daily diets offers a non-pharmacological, low-risk, and cost-effective strategy to manage and prevent T2DM.

Pathophysiology of Diabetes Mellitus

This section now includes clear subheadings, in-depth mechanistic explanations, and logical flow, with references continuing in numerical order from the previous sections.

Pathophysiology of Diabetes Mellitus

Diabetes mellitus, particularly Type 2 diabetes mellitus (T2DM), is a multifactorial metabolic disorder characterized by chronic hyperglycemia due to impaired insulin action, insulin secretion, or both. The pathophysiology of T2DM involves several interconnected mechanisms, including insulin resistance, β-cell dysfunction, chronic low-grade inflammation, oxidative stress, and alterations in gut microbiota. These processes collectively contribute to progressive metabolic dysregulation and long-term complications affecting the cardiovascular, renal, neural, and ocular systems.

INSULIN RESISTANCE AND GLUCOSE DYSREGULATION

Insulin resistance is a central feature of T2DM. It refers to the reduced responsiveness of peripheral tissues—primarily skeletal muscle, adipose tissue, and liver—to the actions of insulin. In healthy individuals, insulin promotes glucose uptake in muscle and fat cells and suppresses hepatic glucose production. In insulin-resistant states, however:

- Skeletal muscles show reduced glucose uptake due to impaired insulin-stimulated GLUT4 translocation.
- Hepatic insulin resistance leads to increased gluconeogenesis and glycogenolysis, contributing to fasting hyperglycemia.
- Adipose tissue releases more free fatty acids (FFAs), which further aggravate insulin resistance and promote lipotoxicity [8]. Initially, the pancreas compensates by secreting more insulin (hyperinsulinemia). However, this is unsustainable and eventually leads to pancreatic β-cell exhaustion [9].

PANCREATIC Β-CELL DYSFUNCTION AND APOPTOSIS

As insulin resistance progresses, pancreatic β-cells—located in the islets of Langerhans—undergo stress due to the increased demand for insulin. This leads to:

1. Endoplasmic reticulum (ER) stress
2. Mitochondrial dysfunction
3. Loss of β-cell identity

Over time, chronic glucotoxicity (damage due to persistent hyperglycemia) and lipotoxicity (excess circulating FFAs) impair β-cell function and promote apoptosis [10]. Importantly, β-cells have low levels of antioxidant enzymes, making them highly susceptible to damage from reactive oxygen species (ROS) [11].

The progressive reduction in β-cell mass and insulin secretion capacity is a key turning point in the transition from prediabetes to overt diabetes.

Chronic Low-Grade Inflammation

Obesity, particularly visceral adiposity, plays a major role in the inflammatory component of T2DM pathogenesis. Enlarged adipocytes and infiltrating macrophages in adipose tissue secrete pro-inflammatory cytokines such as:

- Tumor Necrosis Factor-alpha (TNF-α)
- Interleukin-6 (IL-6)
- C-reactive protein (CRP)

These cytokines interfere with insulin signaling pathways by activating serine kinases such as JNK and IKK-β, which inhibit the insulin receptor substrate (IRS) proteins and impair downstream insulin signaling [12]. This chronic inflammatory state perpetuates insulin resistance and increases the risk of cardiovascular complications in diabetic individuals.

Oxidative Stress and Cellular Damage

Oxidative stress arises when there's an imbalance between ROS production and antioxidant defense mechanisms. In diabetes, several sources contribute to excessive ROS:

i. Hyperglycemia-induced mitochondrial dysfunction
ii. Increased NADPH oxidase activity
iii. Advanced glycation end products (AGEs) [13]
iv. ROS can damage DNA, lipids, and proteins, impair insulin signaling, and promote β-cell apoptosis. Moreover, oxidative stress exacerbates endothelial dysfunction, contributing to microvascular and macrovascular complications [14].

Gut Microbiota and Metabolic Homeostasis

The gut microbiota plays a critical role in energy homeostasis, inflammation, and glucose metabolism. Dysbiosis—an imbalance in microbial composition—has been linked to insulin resistance and obesity. Key mechanisms include:

1. Increased intestinal permeability ("leaky gut"), allowing lipopolysaccharides (LPS) to enter circulation and trigger systemic inflammation.
2. Reduced production of short-chain fatty acids (SCFAs), such as butyrate, which normally enhance insulin sensitivity and modulate appetite.
3. Altered bile acid metabolism and signaling, affecting glucose and lipid pathways [15].
4. Interventions aimed at restoring microbial balance—such as prebiotics, probiotics, and high-fiber diets—have shown promise in improving glycemic control.

Integrated View of Diabetes Pathogenesis

The interplay between insulin resistance, β-cell failure, inflammation, oxidative stress, and gut dysbiosis creates a vicious cycle of metabolic dysfunction. Genetic predisposition and environmental factors (e.g., poor diet, sedentary lifestyle, stress) further accelerate the disease process. Understanding these interconnected mechanisms is essential for developing effective dietary, pharmacological, and lifestyle interventions.

Dietary Patterns and Diabetes

- Mediterranean Diet
- The Mediterranean diet emphasizes:
- Whole grains, fruits, vegetables, legumes
- Healthy fats (olive oil, nuts)
- Moderate fish and poultry consumption
- This diet has been shown to:
- Reduce fasting glucose and HbA1c
- Improve lipid profiles
- Decrease systemic inflammation [20]

DASH Diet

Originally designed for hypertension, the DASH (Dietary Approaches to Stop Hypertension) diet is rich in fruits, vegetables, whole grains, and low-fat dairy. It has demonstrated beneficial effects on insulin sensitivity and blood pressure in T2DM individuals [21].

Low-Carbohydrate and Ketogenic Diets

Low-carb diets (<130 g/day) and very-low-carb ketogenic diets (<50 g/day) promote weight loss and improve glycemic markers. However, long-term adherence and safety require monitoring [22].

Role of Fiber and Whole Grains

Dietary fiber, particularly soluble fiber, delays gastric emptying and carbohydrate absorption, leading to improved postprandial glucose levels. High-fiber diets are associated with:

- Reduced insulin resistance
- Lower HbA1c
- Improved lipid profiles [23]
- Sources of beneficial fibers include oats, legumes, flaxseeds, psyllium husk, and vegetables.

Role of Micronutrients and Phytochemicals

Micronutrients and bioactive plant compounds contribute to glucose regulation and insulin signaling.

- Magnesium improves insulin receptor function and glucose uptake [24].
- Chromium enhances insulin sensitivity and glycemic control [25].
- Polyphenols (e.g., flavonoids, anthocyanins) from berries, tea, and cocoa reduce oxidative stress and modulate glucose metabolism [26].

These compounds are being increasingly incorporated into functional foods for diabetes management.

Caloric Restriction and Intermittent Fasting

Both caloric restriction (CR) and intermittent fasting (IF) can induce metabolic changes that benefit diabetic patients:

- Improved insulin sensitivity
- Reduced oxidative stress
- Weight reduction
- Normalization of circadian rhythms [27]
- Approaches such as time-restricted feeding (TRF) and alternate-day fasting (ADF) have shown promising effects on glycemic variability and β-cell function.

Personalized Nutrition and Glycemic Response

Recent advancements in nutrigenomics and metabolomics have enabled personalized dietary approaches based on an individual's genetic makeup, gut microbiome, and metabolic profile. Personalized meal planning based on postprandial glucose responses can lead to better glycemic control than generalized diet guidelines [28].

Functional Foods and Food-Derived Bioactives in Diabetes Management

Functional foods and food-derived bioactive compounds have emerged as complementary approaches in managing diabetes mellitus, offering therapeutic effects beyond basic nutrition. These components can modulate glucose metabolism, enhance insulin sensitivity, reduce oxidative stress and inflammation, and even protect pancreatic β-cells from damage. The integration of functional foods into daily diets presents a promising strategy for improving metabolic health and preventing diabetic complications.

Definition and Characteristics of Functional Foods

Functional foods are defined as foods that provide health benefits beyond their nutritional value, particularly in the prevention or management of chronic diseases such as diabetes. They may be naturally occurring or fortified with bioactive compounds, such as vitamins, minerals, phytochemicals, or probiotics [29].

- Essential characteristics include:
- Evidence of physiological benefit (e.g., lowering blood glucose)
- Safe for long-term consumption
- Easily integrated into the diet
- Examples: Oats (β-glucans), soy (isoflavones), berries (anthocyanins), cinnamon (polyphenols), yogurt (probiotics).

Mechanisms of Action of Bioactive Compounds

Bioactive compounds in functional foods exert antidiabetic effects through multiple mechanisms, including:

- Enhancing insulin secretion and action
- Reducing postprandial glucose spikes
- Modulating key metabolic enzymes (e.g., α-glucosidase, α-amylase)
- Regulating glucose transporter expression (e.g., GLUT4)
- Suppressing oxidative stress and inflammation [30]
- Major Classes of Food-Derived Bioactives in Diabetes

Polyphenols

Polyphenols are plant-derived antioxidants found in fruits, vegetables, tea, and cocoa. Their antidiabetic actions include:

- Inhibiting carbohydrate-digesting enzymes (α-glucosidase, α-amylase)
- Enhancing insulin sensitivity via AMPK activation
- Modulating gut microbiota and reducing inflammation [31]

Examples:

- Anthocyanins (berries, black rice): Improve insulin resistance
- Flavonoids (onions, apples): Protect β-cells
- Catechins (green tea): Lower fasting glucose

Dietary Fiber and β-Glucans

Fibers from oats, barley, legumes, and fruits slow gastric emptying and reduce glucose absorption.

- Improve postprandial glycemia
- Promote satiety and weight loss
- Fermentable fibers produce short-chain fatty acids (SCFAs), which enhance GLP-1 secretion [32]

Omega-3 Fatty Acids

Present in fatty fish, flaxseeds, and walnuts, omega-3 fatty acids reduce:

- Systemic inflammation
- Triglyceride levels
- Endothelial dysfunction associated with diabetes [33]

Probiotics and Prebiotics

Gut microbiota modulation plays a central role in metabolic regulation. Probiotics (Lactobacillus, Bifidobacterium) and prebiotics (inulin, FOS) improve:

- Intestinal barrier integrity
- Insulin sensitivity
- Glucose homeostasis [34]

Alkaloids and Terpenoids

1. Berberine (found in Berberis species): Activates AMPK pathway, comparable to metformin [35]
2. Curcumin (turmeric): Anti-inflammatory, enhances insulin receptor signaling

Table 1: Examples of Functional Foods with Antidiabetic Potential

Functional Food	Key Bioactive(s)	Mechanism	Effect
Oats	β-glucan	Delays glucose absorption	↓ Postprandial glucose [36]
Cinnamon	Polyphenols	Improves insulin signaling	↓ Fasting glucose [37]
Fenugreek	4-hydroxyisoleucine	Stimulates insulin secretion	↓ HbA1c [38]
Garlic	Organosulfur compounds	Enhances insulin sensitivity	↓ Lipid levels [39]
Bitter Melon	Charantin, Polypeptide-P	Mimics insulin	↓ Glucose levels [40]

Clinical Evidence Supporting Functional Foods in Diabetes

Numerous clinical studies support the efficacy of functional foods:

A randomized trial found cinnamon supplementation (1-6 g/day) significantly reduced fasting blood glucose and triglycerides in T2DM patients [37].

- Oat β-glucans have been shown to lower HbA1c and improve lipid profiles in several trials [36].
- Berberine was reported to reduce blood glucose, HbA1c, and insulin resistance, with effects comparable to metformin in a meta-analysis [35].

Chemical Profiling Techniques for Bioactives in Functional Foods

Understanding the chemical composition of functional foods is essential for evaluating their antidiabetic efficacy and safety. Chemical profiling allows for the identification, quantification, and characterization of bioactive compounds responsible for therapeutic effects. Modern analytical techniques, combined with advanced extraction methods, have significantly enhanced our ability to investigate these compounds with high precision, reproducibility, and sensitivity.

Importance of Chemical Profiling in Functional Foods

1. Chemical profiling is crucial for:
2. Identifying active compounds responsible for antidiabetic properties
3. Establishing standardized dosages in functional food development
4. Ensuring quality control and authenticity
5. Supporting clinical efficacy and safety studies
6. Discovering new bioactive compounds for therapeutic use [41]

Sample Preparation and Extraction Techniques

Proper sample preparation is vital to ensure efficient extraction of bioactives. Common extraction techniques include:

- Solvent Extraction: Using solvents like ethanol, methanol, or water to extract phenolics, flavonoids, and alkaloids [42].
- Ultrasound-Assisted Extraction (UAE): Increases yield and efficiency through ultrasonic waves [43].
- Supercritical Fluid Extraction (SFE): Utilizes supercritical CO_2 for non-polar compounds (e.g., terpenes, lipids) [44].
- Microwave-Assisted Extraction (MAE): Enhances heat and mass transfer for polar and semi-polar compounds [45].

These methods are often selected based on the physicochemical properties of the target bioactives.

- Chromatographic Techniques
- High-Performance Liquid Chromatography (HPLC)
- Widely used to separate and quantify polyphenols, flavonoids, and alkaloids.
- Coupled with UV-Vis, DAD, or MS detectors for enhanced detection [46].

Gas Chromatography (GC)

- Suitable for volatile and thermally stable compounds like fatty acids, essential oils, and sterols.
- Commonly used with FID or GC-MS detection systems [47].

Thin Layer Chromatography (TLC)

- Simple and cost-effective method for preliminary screening.
- Commonly used in herbal and traditional medicine profiling [48].

Spectroscopic Techniques
Mass Spectrometry (MS)

- Offers high-resolution identification of unknown bioactives.
- Often used in tandem with HPLC or GC for structural elucidation [49].

Nuclear Magnetic Resonance (NMR)

- Provides structural and conformational information about complex molecules.
- Especially useful for quantifying multiple metabolites in a single run [50].

Fourier-Transform Infrared Spectroscopy (FTIR)

- Offers functional group identification and fingerprinting.
- Useful in detecting phenolics, proteins, and carbohydrates [51].

Metabolomics and Chemometrics in Functional Food Analysis

The integration of metabolomics and chemometric tools has revolutionized food analysis. These approaches help in:

- Identifying metabolite biomarkers associated with antidiabetic effects
- Comparing metabolic profiles of different food sources
- Ensuring batch-to-batch consistency in commercial products [52]
- Advanced software like MetaboAnalyst and SIMCA is used to handle large datasets and derive meaningful correlations.

Case Studies

- Berberine profiling using HPLC-MS/MS revealed its main alkaloid components responsible for glucose-lowering effects [53].
- Green tea polyphenols such as EGCG were identified and quantified using HPLC-DAD and NMR, confirming their anti-insulin resistance properties [54].
- Curcumin content in turmeric extracts was validated by UV-VIS and FTIR spectroscopy for use in standardized nutraceuticals [55].

Clinical Evidence and Human Trials on Functional Foods in Diabetes Management

The transition from in vitro and animal studies to clinical trials is vital for validating the antidiabetic efficacy and safety of functional foods in human populations. Numerous randomized controlled trials (RCTs) have evaluated food-derived bioactive compounds in individuals with prediabetes or type 2 diabetes mellitus (T2DM), yielding promising results in improving glycemic control, insulin sensitivity, and metabolic markers.

Role of Clinical Trials in Evidence-Based Nutrition

Clinical trials:

- Confirm the real-world effectiveness of functional foods
- Assess bioavailability, dosage, and safety in diverse populations
- Provide statistical evidence for regulatory approval and health claims [56]
- Bridge the gap between laboratory studies and therapeutic recommendations

Key Findings from Clinical Studies

Polyphenol-Rich Foods

Polyphenols such as flavonoids, anthocyanins, and catechins have been widely studied in clinical settings:

- Green tea polyphenols (EGCG): A double-blind RCT reported that 12-week supplementation with green tea extract significantly reduced fasting blood glucose and HbA1c in T2DM patients [57].
- Blueberry anthocyanins: Daily consumption of blueberry powder improved insulin sensitivity and reduced oxidative stress markers in obese insulin-resistant individuals [58].

Fiber-Enriched Diets

Dietary fibers, especially soluble fibers, delay gastric emptying and carbohydrate absorption:

- A clinical study found that supplementation with beta-glucan from oats lowered postprandial glucose and improved insulin response in adults with T2DM [59].
- Psyllium fiber intake was associated with a significant reduction in HbA1c and fasting plasma glucose [60].

Cinnamon and Curcumin

A meta-analysis of RCTs showed that Cinnamon (Cinnamomum cassia) intake significantly reduced fasting blood glucose and total cholesterol levels in T2DM patients [61]. Curcumin, derived from turmeric, improved pancreatic β-cell function and reduced insulin resistance when administered over 9 months to prediabetic individuals, delaying the progression to T2DM [62].

Fermented Foods and Probiotics

Probiotic supplementation influences gut microbiota and improves metabolic outcomes: A clinical trial with Lactobacillus and Bifidobacterium strains showed improved glycemic control, lipid profiles, and inflammatory markers in T2DM patients [63].

Whole Plant-Based Diets

Long-term intervention with Mediterranean and plant-based diets led to reduced HbA1c and body weight, improved lipid profiles, and decreased need for anti-diabetic medications [64].

Limitations of Current Clinical Evidence

While clinical trials provide valuable insights, some limitations remain:

- Small sample sizes and short durations limit the generalizability of results.
- Variability in bioactive content due to food processing or regional differences.
- Lack of standardization in functional food formulations.
- Difficulty in isolating the specific effects of individual bioactives within a mixed diet [65].

Recommendations for Future Clinical Research

- Design long-term, multicenter trials with larger cohorts.
- Use standardized and quantified extracts for consistency.
- Include biomarker-based endpoints to understand mechanisms.
- Explore synergistic effects of combined bioactives.

Mechanisms of Action of Bioactive Compounds in Diabetes Prevention and Treatment

Understanding the mechanisms of action through which bioactive compounds influence glucose homeostasis, insulin sensitivity, and metabolic regulation is critical for designing effective dietary strategies. Functional food-derived bioactives act on multiple targets within metabolic and signaling pathways, enabling them to modulate the pathophysiological processes of diabetes at molecular and cellular levels.

Enhancement of Insulin Secretion and β-Cell Protection

Several phytochemicals improve pancreatic β-cell function by:

- Stimulating insulin secretion via depolarization of β-cell membranes and increasing intracellular calcium influx (e.g., flavonoids, saponins)
- Reducing oxidative and ER stress, protecting β-cells from apoptosis [66]
- Enhancing expression of genes such as Pdx1, Ins1, and Glut2, crucial for insulin biosynthesis and β-cell health [67]
- For example, curcumin and resveratrol have been shown to restore β-cell mass and function in diabetic models [68].

Improvement of Insulin Sensitivity

Bioactive compounds enhance insulin sensitivity by modulating insulin signaling pathways:

1. Activation of AMP-activated protein kinase (AMPK), which promotes glucose uptake and fatty acid oxidation (e.g., berberine, polyphenols)
2. Upregulation of GLUT4 expression in skeletal muscle and adipose tissue, increasing peripheral glucose uptake [69]
3. Inhibition of negative regulators like protein tyrosine phosphatase 1B (PTP1B) [70]
4. Cinnamon polyphenols have demonstrated insulin-like effects by enhancing insulin receptor autophosphorylation [71].

Inhibition of Carbohydrate-Digesting Enzymes

Functional food compounds can delay glucose absorption by inhibiting enzymes involved in carbohydrate digestion:

α-amylase and α-glucosidase inhibition slows starch breakdown and reduces postprandial hyperglycemia, Common inhibitors include tannins, flavonoids, and phenolic acids found in legumes, berries, and green tea [72]. This mechanism mimics the pharmacological action of drugs like acarbose, but with fewer gastrointestinal side effects.

Antioxidant and Anti-Inflammatory Effects

Oxidative stress and inflammation are major contributors to insulin resistance and β-cell dysfunction. Bioactive compounds:

- Scavenge ROS and enhance endogenous antioxidant enzymes such as SOD, catalase, and glutathione peroxidase [73]
- Suppress pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6 by inhibiting NF-κB and MAPK pathways [74]
- For instance, anthocyanins and quercetin reduce oxidative markers and inflammatory cytokine levels in diabetic patients [75].

Modulation of Gut Microbiota

Dietary bioactives influence gut microbiota composition, which in turn affects glucose metabolism and inflammation: Promote growth of beneficial bacteria (e.g., Bifidobacteria, Lactobacillus), Increase production of short-chain fatty acids (SCFAs) like butyrate, which improve insulin sensitivity, Decrease intestinal permeability and endotoxin (LPS) translocation, reducing systemic inflammation [76], Prebiotic fibers, polyphenols, and fermented foods are key modulators of the gut-metabolic axis.

Regulation of Adipokines and Lipid Metabolism

Functional foods improve lipid profiles and modulate adipokine secretion:

- Increase in adiponectin, which enhances insulin sensitivity and fatty acid oxidation
- Decrease in leptin and resistin, which are elevated in obesity and insulin resistance [77]
- Downregulation of SREBP-1c and FAS, leading to reduced lipogenesis
- Omega-3 fatty acids, found in nuts and fatty fish, have shown lipid-lowering and insulin-sensitizing effects via these pathways [78].

Epigenetic Modifications and Gene Expression

Emerging evidence shows that bioactives can exert epigenetic effects:

Modulate DNA methylation and histone acetylation, influencing gene expression related to metabolism, Activate miRNAs involved in insulin signaling, oxidative stress, and inflammation [79], Compounds like EGCG (from green tea) and sulforaphane (from broccoli) have shown epigenetic activity beneficial for metabolic regulation [80].

Safety, Regulatory Status, and Consumer Acceptance of Functional Foods in Diabetes

The development and integration of functional foods and food-derived bioactive compounds in the management of diabetes require careful consideration of safety, regulatory compliance, and consumer perceptions. As functional foods bridge the gap between nutrition and pharmacology, they must meet both food and health product regulations to ensure efficacy and safety.

Safety Evaluation of Bioactive Compounds

Although many bioactive compounds are derived from natural sources, their safety cannot be assumed without rigorous evaluation. Potential concerns include:

- Toxicity at high doses or upon long-term consumption
- Adverse interactions with medications (e.g., flavonoids interfering with drug metabolism via cytochrome P450)
- Allergenic potential in sensitive individuals [81]
- Bioaccumulation and metabolite toxicity in the liver or kidneys
- For example, high doses of berberine may lead to gastrointestinal discomfort or hepatic stress [82]. Therefore, standardized toxicity assessments including LD50, NOAEL, and chronic exposure studies are essential before recommending functional foods clinically.

Regulatory Framework and Guidelines

Functional foods and nutraceuticals fall under various regulatory categories across countries. Regulatory oversight ensures product safety, prevents misleading health claims, and protects consumers. In the United States, the FDA classifies functional foods as dietary supplements under the DSHEA (1994), requiring Good Manufacturing Practices (GMP) but not pre-market approval unless novel ingredients are used [83]. In the European Union, EFSA evaluates health claims based on scientific evidence under Regulation (EC) No. 1924/2006 [84].

Japan, a pioneer in functional food regulation, introduced FOSHU (Foods for Specified Health Uses), which mandates clinical evidence and government approval [85]. Inconsistent global regulation can be a challenge for companies aiming to market functional food products internationally.

Consumer Acceptance and Market Trends

Consumer acceptance of functional foods for diabetes depends on several factors:

- Perceived naturalness and safety: Consumers prefer plant-based solutions with minimal processing [86].
- Taste, appearance, and convenience are critical for long-term adherence. Bitter taste of polyphenols may affect product desirability unless masked.
- Awareness and education about diabetes and functional food benefits influence willingness to adopt dietary changes [87].

- Cultural beliefs and dietary habits also play a role, particularly in regions with traditional medicine systems like Ayurveda or TCM (Traditional Chinese Medicine).
- Global functional food markets are expanding rapidly, driven by growing diabetes prevalence and interest in preventive health. However, addressing skepticism, ensuring label transparency, and conducting well-designed human trials remain essential to build consumer trust.

Need for Clinical Validation

Despite promising in vitro and animal studies, many functional foods lack robust clinical evidence to support antidiabetic claims. Most studies suffer from:

- Small sample sizes
- Short durations
- Lack of standardized formulations and biomarkers
- Variability in diet, lifestyle, and genetic background

More randomized controlled trials (RCTs) are needed to validate safety, efficacy, and optimal dosing of food-derived bioactives in diabetic populations [88].

Challenges, Limitations, and Future Directions

Despite significant progress in identifying food-derived bioactives for diabetes management, several scientific, regulatory, and translational challenges hinder their successful integration into mainstream clinical practice. Recognizing these limitations is essential to bridge the gap between laboratory research and real-world application.

Variability in Bioactive Composition and Bioavailability

A key challenge lies in the variability of bioactive compound composition due to differences in:

- Plant cultivar and growing conditions
- Harvesting, storage, and processing methods
- Extraction and formulation techniques [89]

Moreover, many bioactives suffer from poor bioavailability, owing to limited solubility, rapid metabolism, or poor intestinal absorption. For example:

Curcumin is poorly absorbed, extensively metabolized, and rapidly eliminated
Polyphenols undergo significant degradation by gut microbiota before systemic absorption [90]
Advanced delivery systems such as nanoencapsulation, liposomes, and emulsions are being explored to enhance stability and bioavailability [91].

Inconsistencies in Preclinical and Clinical Data

Many promising results in in vitro and animal models have failed to translate into human clinical efficacy due to:

- Biological complexity of human metabolism
- Differences in dosage, duration, and bioactive form used
- Lack of standardized protocols and biomarkers [92]
- Some compounds show dual effects based on concentration or physiological context, making dose-response relationships difficult to establish.

Regulatory and Standardization Hurdles

The absence of harmonized international regulations on functional foods complicates their market approval. Key limitations include:

1. No clear guidelines for acceptable daily intake of most bioactives
2. Varying definitions of "functional food" across jurisdictions
3. Insufficient evidence required for structure-function claims in some countries [93]
4. Establishing standardized testing protocols, product labeling, and evidence-based health claims is crucial for consumer safety and trust.

Consumer Awareness and Acceptance Barriers

Although consumer interest in functional foods is growing, challenges remain:

- Lack of awareness about specific health benefits of food bioactives
- Mistrust due to overhyped marketing and unsubstantiated claims
- Sensory and taste issues due to the bitterness or strong odor of some bioactive ingredients (e.g., bitter gourd, garlic) [94]
- Educational initiatives and scientifically supported messaging can improve consumer confidence and adoption.

Future Directions

To overcome current limitations and optimize the role of functional foods in diabetes management, future efforts should focus on:

- Integrative omics approaches (genomics, metabolomics, nutrigenomics) to understand individual responses to dietary bioactives
- Personalized nutrition strategies based on genetic, metabolic, and microbiome profiles [95]
- More robust randomized controlled trials (RCTs) to confirm efficacy, safety, and dosage of functional food interventions
- Development of multifunctional foods combining synergistic bioactives to target multiple diabetes-related pathways
- Improved public-private partnerships to fund translational research and support innovation in food formulation and delivery technologies [96]
- The future of functional foods lies in precision nutrition, which tailors dietary interventions to an individual's unique biology, lifestyle, and disease risk.

CONCLUSION

The rising global burden of diabetes demands innovative, sustainable, and accessible strategies for prevention and management. Functional foods enriched with food-derived bioactive compounds offer a natural, non-pharmacological approach to support metabolic health and glycemic control. As explored in this review, various classes of bioactives—including polyphenols, flavonoids, alkaloids, peptides, and fibers—have shown antidiabetic potential through mechanisms such as modulation of insulin sensitivity, glucose metabolism, gut microbiota, oxidative stress, and inflammation. These compounds, found in commonly consumed plant-based foods, spices, legumes, and whole grains, are increasingly being incorporated into functional food products targeted toward diabetic populations. However, challenges related to bioavailability, standardization, regulatory oversight, and clinical validation must be addressed. A more personalized nutrition approach, supported by advances in omics technologies, can enhance the efficacy and acceptability of these dietary interventions. Moreover, consumer education, transparent labeling, and well-regulated health claims are essential to build trust in functional food solutions. The future of diabetes management will likely involve synergistic strategies combining diet, lifestyle modifications, pharmacotherapy, and functional nutrition. To that end, functional foods and nutraceuticals—grounded in strong scientific evidence—can play a pivotal role in improving metabolic health and reducing the global diabetes burden.

REFERENCES

1. International Diabetes Federation. (2021). *IDF Diabetes Atlas* (10th ed.). Brussels, Belgium: IDF.
2. Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., ... & Williams, R. (2019). Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Research and Clinical Practice*, 157, 107843.
3. World Health Organization. (2020). *Diabetes*. https://www.who.int/news-room/fact-sheets/detail/diabetes
4. American Diabetes Association. (2021). Standards of Medical Care in Diabetes—2021. *Diabetes Care*, 44(Suppl 1), S1–S232.
5. Ley, S. H., Hamdy, O., Mohan, V., & Hu, F. B. (2014). Prevention and management of type 2 diabetes: Dietary components and nutritional strategies. *The Lancet*, 383(9933), 1999–2007.
6. Ganesan, K., & Xu, B. (2017). Polyphenol-rich dry common beans (Phaseolus vulgaris L.) and their health benefits. *International Journal of Molecular Sciences*, 18(11), 2331.
7. Roberfroid, M. B. (2002). Functional foods: Concepts and application to inulin and oligofructose. *British Journal of Nutrition*, 87(S2), S139–S143.
8. Martirosyan, D., & Singh, J. (2015). A new definition of functional food by FFC: What makes a new definition unique? *Functional Foods in Health and Disease*, 5(6), 209–223.
9. Espín, J. C., García-Conesa, M. T., & Tomás-Barberán, F. A. (2007). Nutraceuticals: Facts and fiction. *Phytochemistry*, 68(22–24), 2986–3008.
10. Liu, R. H. (2004). Potential synergy of phytochemicals in cancer prevention: Mechanism of action. *The Journal of Nutrition*, 134(12), 3479S–3485S.
11. Vinayagam, R., & Xu, B. (2015). Antidiabetic properties of dietary flavonoids: A cellular mechanism review. *Nutrition & Metabolism*, 12, 60.
12. Laleh, G., Ali, R., Seyed, A. M., & Arezoo, R. (2020). Flavonoids as potent antidiabetic agents. *Bioorganic Chemistry*, 92, 103236.
13. Eid, H. M., Haddad, P. S. (2017). The antidiabetic potential of quercetin: Underlying mechanisms. *Current Medicinal Chemistry*, 24(4), 355–364.
14. Zhang, Y., Wang, Y., Wang, X., Wang, C., & Li, X. (2016). Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. *PLoS ONE*, 11(2), e0148449.
15. Ji, L., Li, H., Guo, L., Ren, J., & Liu, J. (2018). Inhibitory effects of berberine on α-glucosidase activity in vitro and in vivo. *Journal of Enzyme Inhibition and Medicinal Chemistry*, 33(1), 1016–1023.
16. Patel, D. K., Prasad, S. K., Kumar, R., & Hemalatha, S. (2012). An overview on antidiabetic medicinal plants having insulin mimetic property. *Asian Pacific Journal of Tropical Biomedicine*, 2(4), 320–330.
17. Li, Y., Tran, V. H., Duke, C. C., & Roufogalis, B. D. (2012). Gingerols of Zingiber officinale enhance glucose uptake by increasing cell surface GLUT4 in cultured L6 myotubes. *Planta Medica*, 78(14), 1549–1555.
18. Mohan, V., Radhika, G., Sathya, R. M., & Ganesan, A. (2010). Dietary carbohydrates, glycemic load, food groups and newly detected type 2 diabetes among urban Asian Indian population in Chennai, India (Chennai Urban Rural Epidemiology Study 59). *British Journal of Nutrition*, 102(10), 1498–1506.
19. Hanhineva, K., Törrönen, R., Bondia-Pons, I., Pekkinen, J., Kolehmainen, M., Mykkänen, H., & Poutanen, K. (2010). Impact of dietary polyphenols on carbohydrate metabolism. *International Journal of Molecular Sciences*, 11(4), 1365–1402.
20. Blaak, E. E., Canfora, E. E., Theis, S., Frost, G., Groen, A. K., Mithieux, G., ... & Holst, J. J. (2020). Short chain fatty acids in human gut and metabolic health. *Nature Reviews Endocrinology*, 16(7), 461–478.
21. Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016). From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. *Cell*, 165(6), 1332–1345.

22. de Vos, W. M., & Nieuwdorp, M. (2013). Genomics: A gut prediction. *Nature*, 498(7452), 48–49.
23. Nicholson, J. K., Holmes, E., Kinross, J., Burcelin, R., Gibson, G., Jia, W., & Pettersson, S. (2012). Host-gut microbiota metabolic interactions. *Science*, 336(6086), 1262–1267.
24. Rastmanesh, R. (2011). High polyphenol, low probiotic diet for weight loss because of intestinal microbiota interaction. *Chemico-Biological Interactions*, 189(1–2), 1–8.
25. Wang, X., & Gibson, G. R. (2017). Prebiotics and their role in improving gut health. *Food Science and Human Wellness*, 6(1), 41–47.
26. Yadav, H., Jain, S., & Sinha, P. R. (2007). Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. *Nutrition*, 23(1), 62–68.
27. Delzenne, N. M., Neyrinck, A. M., & Cani, P. D. (2013). Gut microbiota and metabolic disorders: How prebiotic can work? *British Journal of Nutrition*, 109(S2), S81–S85.
28. Vinik, A. I., & Vinik, E. J. (2003). Prevention of the complications of diabetes. *The American Journal of Managed Care*, 9(3), S63–S80.
29. Hardy, M. L. (2000). Herbs of special interest to women. *Journal of the American Pharmaceutical Association*, 40(2), 234–242.
30. Kong, W. J., Wei, J., Zuo, Z. Y., Wang, Y. M., Song, D. Q., You, X. F., ... & Jiang, J. D. (2008). Combination of simvastatin with berberine improves the lipid-lowering efficacy. *Metabolism*, 57(8), 1029–1037.
31. U.S. Food and Drug Administration. (1994). *Dietary Supplement Health and Education Act (DSHEA)*. https://www.fda.gov
32. European Food Safety Authority (EFSA). (2016). Scientific and technical guidance for health claim applications. *EFSA Journal*, 14(1), 4367.
33. Iwai, K., & Moriyama, H. (2015). Functional food products and FOSHU in Japan. In *Nutraceutical and Functional Food Regulations in the United States and Around the World* (2nd ed.). Academic Press.
34. Annunziata, A., & Vecchio, R. (2011). Functional foods development in the European market: Consumer perspective. *Trends in Food Science & Technology*, 22(11), 590–598.
35. Bech-Larsen, T., & Grunert, K. G. (2003). The perceived healthiness of functional foods: A conjoint study of Danish, Finnish and American consumers' perception. *Appetite*, 40(1), 9–14.
36. Hosseini, S. F., Jafari, S. M., & Ziaee, E. (2020). Application of nano/microencapsulated natural antioxidants in functional foods. *Food Research International*, 137, 109724.
37. Manach, C., Scalbert, A., Morand, C., Rémésy, C., & Jiménez, L. (2004). Polyphenols: Food sources and bioavailability. *The American Journal of Clinical Nutrition*, 79(5), 727–747.
38. D'Archivio, M., Filesi, C., Vari, R., Scazzocchio, B., & Masella, R. (2010). Bioavailability of polyphenols: Status and controversies. *International Journal of Molecular Sciences*, 11(4), 1321–1342.
39. McClements, D. J. (2018). Delivery by design (DbD): A standardized approach to the development of efficacious nanoparticle- and microparticle-based delivery systems. *Comprehensive Reviews in Food Science and Food Safety*, 17(1), 200–219.
40. Yao, L. H., Jiang, Y. M., Shi, J., Tomás-Barberán, F. A., Datta, N., Singanusong, R., & Chen, S. S. (2004). Flavonoids in food and their health benefits. *Plant Foods for Human Nutrition*, 59(3), 113–122.
41. Hasler, C. M. (2002). Functional foods: Benefits, concerns and challenges. *The Journal of Nutrition*, 132(12), 3772–3781.
42. Binns, C. W., Lee, M. K., & Lee, A. H. (2010). Problems and prospects: Public health regulation of functional foods in Australia, Canada, Japan and the USA. *Food Control*, 21(3), 251–256.
43. Ferguson, L. R. (2009). Nutrigenomics approaches to functional foods. *Journal of the American Dietetic Association*, 109(3), 452–458.
44. Ubbink, J. B. (2013). Nutrition science: From reductionism to systems biology. *Food & Function*, 4(2), 131–137.
45. Ceriello, A., & Motz, E. (2004). Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 24(5), 816–823.
46. Tilg, H., & Moschen, A. R. (2014). Microbiota and diabetes: An evolving relationship. *Gut*, 63(9), 1513–1521.
47. Post, R. E., Mainous, A. G., King, D. E., & Simpson, K. N. (2012). Dietary fiber for the treatment of type 2 diabetes mellitus: A meta-analysis. *Journal of the American Board of Family Medicine*, 25(1), 16–23.
48. Barbagallo, M., & Dominguez, L. J. (2015). Magnesium and type 2 diabetes. *World Journal of Diabetes*, 6(10), 1152–1157.
49. Anderson, R. A. (2003). Chromium and insulin resistance. *Nutrition Research Reviews*, 16(2), 267–275.
50. Longo, V. D., & Panda, S. (2016). Fasting, circadian rhythms, and time-restricted feeding in healthy lifespan. *Cell Metabolism*, 23(6), 1048–1059.
51. Zeevi, D., Korem, T., Zmora, N., et al. (2015). Personalized nutrition by prediction of glycemic responses. *Cell*, 163(5), 1079–1094.
52. Minihane, A. M., Vinoy, S., Russell, W. R., et al. (2015). Low-grade inflammation, diet composition and health: Current research evidence and its translation. *British Journal of Nutrition*, 114(7), 999–1012.

53. Liu, K., Zhou, R., Wang, B., et al. (2013). Effect of green tea on glucose control and insulin sensitivity: A meta-analysis of 17 randomized controlled trials. *American Journal of Clinical Nutrition*, 98(2), 340–348.
54. Stull, A. J., Cash, K. C., Johnson, W. D., et al. (2010). Bioactives in blueberries improve insulin sensitivity in obese, insulin-resistant men and women. *The Journal of Nutrition*, 140(10), 1764–1768.
55. Tosh, S. M. (2013). Review of human studies investigating the postprandial blood-glucose lowering ability of oat and barley food products. *European Journal of Clinical Nutrition*, 67(4), 310–317.
56. Pal, S., Khossousi, A., Binns, C., et al. (2011). The effects of psyllium on metabolic syndrome risk factors. *Journal of Obesity*, 2011, Article 1–8.
57. Allen, R. W., Schwartzman, E., Baker, W. L., et al. (2013). Cinnamon use in type 2 diabetes: An updated systematic review and meta-analysis. *Annals of Family Medicine*, 11(5), 452–459.
58. Chuengsamarn, S., Rattanamongkolgul, S., Luechapudiporn, R., et al. (2012). Curcumin extract for prevention of type 2 diabetes. *Diabetes Care*, 35(11), 2121–2127.
59. Sabico, S., Al-Mashharawi, A., Al-Daghri, N. M., et al. (2015). Effects of a 6-month multistrain probiotic supplementation in T2DM subjects. *Journal of Translational Medicine*, 13, 290.
60. Esposito, K., Maiorino, M. I., Ceriello, A., & Giugliano, D. (2010). Prevention and control of type 2 diabetes by Mediterranean diet: A systematic review. *Diabetes Research and Clinical Practice*, 89(2), 97–102.
61. Vuksan, V., & Sievenpiper, J. L. (2005). Herbal remedies in the management of diabetes: Lessons learned from the study of ginseng. *Nutrition, Metabolism & Cardiovascular Diseases*, 15(3), 149–160.
62. Hardy, M. L. (2000). Herbs of special interest to women. *Journal of the American Pharmaceutical Association*, 40(2), 234–242.
63. Kong, W. J., Wei, J., Zuo, Z. Y., et al. (2008). Combination of simvastatin with berberine improves the lipid-lowering efficacy. *Metabolism*, 57(8), 1029–1037.
64. U.S. Food and Drug Administration. (1994). *Dietary Supplement Health and Education Act (DSHEA)*. Washington, DC: FDA.
65. European Food Safety Authority. (2016). Scientific and technical guidance for health claim applications. *EFSA Journal*, 14(1), 4367.
66. Iwai, K., & Moriyama, H. (2015). Functional food products and FOSHU in Japan. In *Nutraceutical and Functional Food Regulations in the United States and Around the World* (2nd ed.). Academic Press.
67. Annunziata, A., & Vecchio, R. (2011). Functional foods development in the European market: Consumer perspective. *Trends in Food Science & Technology*, 22(11), 590–598.
68. Bech-Larsen, T., & Grunert, K. G. (2003). The perceived healthiness of functional foods: A conjoint study of Danish, Finnish and American consumers' perception. *Appetite*, 40(1), 9–14.
69. Hosseini, S. F., Jafari, S. M., & Ziaee, E. (2020). Application of nano/micro-encapsulated natural antioxidants in functional foods. *Food Research International*, 137, 109724.
70. Manach, C., Scalbert, A., Morand, C., Rémésy, C., & Jiménez, L. (2004). Polyphenols: Food sources and bioavailability. *American Journal of Clinical Nutrition*, 79(5), 727–747.
71. D'Archivio, M., Filesi, C., Vari, R., Scazzocchio, B., & Masella, R. (2010). Bioavailability of polyphenols: Status and controversies. *International Journal of Molecular Sciences*, 11(4), 1321–1342.
72. McClements, D. J. (2018). Delivery by design (DbD): A standardized approach to the development of efficacious nanoparticle- and microparticle-based delivery systems. *Comprehensive Reviews in Food Science and Food Safety*, 17(1), 200–219.
73. Yao, L. H., Jiang, Y. M., Shi, J., et al. (2004). Flavonoids in food and their health benefits. *Plant Foods for Human Nutrition*, 59(3), 113–122.
74. Hasler, C. M. (2002). Functional foods: Benefits, concerns and challenges—a position paper from the American Council on Science and Health. *The Journal of Nutrition*, 132(12), 3772–3781.
75. Binns, C. W., Lee, M. K., & Lee, A. H. (2010). Problems and prospects: Public health regulation of functional foods in Australia, Canada, Japan and the USA. *Food Control*, 21(3), 251–256.
76. Ferguson, L. R. (2009). Nutrigenomics approaches to functional foods. *Journal of the American Dietetic Association*, 109(3), 452–458.
77. Ubbink, J. B. (2013). Nutrition science: From reductionism to systems biology. *Food & Function*, 4(2), 131–137.
78. DeFronzo, R. A. (2010). Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: The missing links. *Diabetologia*, 53(7), 1270–1287.
79. Prentki, M., & Nolan, C. J. (2006). Islet β-cell failure in type 2 diabetes. *Journal of Clinical Investigation*, 116(7), 1802–1812.
80. Robertson, R. P. (2004). Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. *The Journal of Biological Chemistry*, 279(41), 42351–42354.
81. Evans, J. L., Goldfine, I. D., Maddux, B. A., & Grodsky, G. M. (2002). Oxidative stress and stress-activated signaling pathways: A unifying hypothesis of type 2 diabetes. *Endocrine Reviews*, 23(5), 599–622.
82. Shoelson, S. E., Lee, J., & Goldfine, A. B. (2006). Inflammation and insulin resistance. *Journal of Clinical Investigation*, 116(7), 1793–1801.

83. Brownlee, M. (2005). The pathobiology of diabetic complications: A unifying mechanism. *Diabetes*, 54(6), 1615–1625.
84. Shahidi, F., & Ambigaipalan, P. (2015). Phenolics and polyphenolics in foods, beverages and spices: Antioxidant activity and health effects – A review. *Journal of Functional Foods*, 18, 820–897.
85. Azwanida, N. N. (2015). A review on the extraction methods used in medicinal plants: principles, strengths and limitations. *Medicinal & Aromatic Plants*, 4(3), 196.
86. Chemat, F., Zill-e-Huma, & Khan, M. K. (2011). Applications of ultrasound in food technology: Processing, preservation and extraction. *Ultrasonics Sonochemistry*, 18(4), 813–835.
87. Herrero, M., Cifuentes, A., & Ibáñez, E. (2006). Sub- and supercritical fluid extraction of functional ingredients from different natural sources: Plants, food-by-products, algae and microalgae. *Food Chemistry*, 98(1), 136–148.
88. Mandal, V., Mohan, Y., & Hemalatha, S. (2007). Microwave-assisted extraction—An innovative and promising extraction tool for medicinal plant research. *Pharmacognosy Reviews*, 1(1), 7–18.
89. Stalikas, C. D. (2007). Extraction, separation, and detection methods for phenolic acids and flavonoids. *Journal of Separation Science*, 30(18), 3268–3295.
90. Dugo, G., & Mondello, L. (2011). Comprehensive chromatographic fingerprinting of food and herbal products. *Journal of Chromatographic Science*, 49(3), 196–205.
91. Wagner, H., & Bladt, S. (1996). *Plant drug analysis: A thin layer chromatography atlas*. Springer.
92. Dettmer, K., Aronov, P. A., & Hammock, B. D. (2007). Mass spectrometry-based metabolomics. *Mass Spectrometry Reviews*, 26(1), 51–78.
93. Emwas, A. H. (2015). The strengths and weaknesses of NMR spectroscopy and mass spectrometry with particular focus on metabolomics research. In *Methods in Molecular Biology* (Vol. 1277, pp. 161–193).
94. Sivakesava, S., & Irudayaraj, J. (2002). Detection of fungal infection in strawberries using mid-infrared spectroscopy. *Transactions of the ASAE*, 45(3), 725–730.
95. Gika, H. G., Theodoridis, G. A., Wilson, I. D., & Trygg, J. (2010). Challenges and opportunities in the application of chemometrics to LC–MS- and NMR-based metabolomics. *Bioanalysis*, 2(19), 2923–2942.
96. Zuo, F., Zhou, Z. M., Liu, M. L., et al. (2006). Analysis of berberine and related compounds by HPLC-ESI-MS/MS. Biomedical Chromatography, 20(3), 197–204.